STILL NOT ENOUGH
Astrazeneca rebuffs new $107.94B offer from Pfizer
By Nuala Moran
Monday, May 5, 2014
LONDON It took Astrazeneca plc just a little over three hours on Friday morning to reject an improved £50 (US$84.32) per share offer from Pfizer Inc., valuing the UK company at about £64 billion (US$107.94 billion), saying the terms are inadequate, substantially undervaluing Astrazeneca and are not a basis on which to engage.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.